Fitbit Inc (NYSE:FIT) jumped 9.13% in pre-market trading following the long weekend to $34.
Endocyte, Inc. (NASDAQ:ECYT) presented the final overall survival (OS) analysis from the Phase 2b TARGET trial evaluating its small molecule drug conjugate (SMDC) vintafolide …
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results …
Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in …
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in …
Cantor analyst Daniel Brims was out pounding the table on Endocyte, Inc. (NASDAQ:ECYT), reiterating an Outperform rating and a $21.
